Asterias Biotherapeutics Stock Price, News & Analysis (NYSEAMERICAN:AST)

$2.45 -0.05 (-2.00 %)
(As of 11/17/2017 12:51 PM ET)
Previous Close$2.45
Today's Range$2.45 - $2.60
52-Week Range$2.00 - $5.80
Volume64,252 shs
Average Volume222,162 shs
Market Capitalization$130.02 million
P/E RatioN/A
Dividend YieldN/A

About Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Previous Symbol: NYSEMKT:AST
  • CUSIP: N/A
  • Web:
  • Trailing EPS: ($0.65)
  • Net Margins: -2,762.03%
  • Return on Equity: -86.25%
  • Return on Assets: -66.19%
  • Outstanding Shares: 54,150,000

Frequently Asked Questions for Asterias Biotherapeutics (NYSEAMERICAN:AST)

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to analyst estimates of $2.81 million. Asterias Biotherapeutics had a negative net margin of 2,762.03% and a negative return on equity of 86.25%. View Asterias Biotherapeutics' Earnings History.

Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2017?

3 brokers have issued 1 year price objectives for Asterias Biotherapeutics' stock. Their predictions range from $10.00 to $12.00. On average, they expect Asterias Biotherapeutics' stock price to reach $11.33 in the next twelve months. View Analyst Ratings for Asterias Biotherapeutics.

What are Wall Street analysts saying about Asterias Biotherapeutics stock?

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:

  • 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (10/25/2017)
  • 2. HC Wainwright analysts commented, "We remind investors that the company continues to advance the SCiStar Phase 2 trial of AST-OPC1, its lead clinical program, which is enrolling both complete cervical SCI patients (AIS A classification), who have no sensory or motor function at the lowest sacral level on the ASIA impairment scale, and incomplete cervical SCI patients (AIS B classification), who retain some sensory function but no motor function at this level. Among the five cohorts slated to be treated in the trial, the first two have completed enrollment of three and six subjects respectively. Cohort 3, which comprises AIS-A patients treated with 20M cells, should generate six-month efficacy data in 3Q17. Cohort 4, which is composed of AIS- B patients, should also generate six-month efficacy data in late 3Q17. Finally, Cohort 5, which is to enroll five to eight AIS-B subjects for treatment with 20M cells per patient, could complete enrollment in 3Q17 with six-month data available in early 2018." (3/30/2017)
  • 3. FBR & Co analysts commented, "We are transferring coverage of Asterias Biotherapeutics, Inc. (AST) and maintaining our Outperform rating, but we are lowering our price target to $6 (from $10) to reflect a more conservative view. AST is developing therapies in an area of immense promise that can change the practice of medicine. However, the emerging field of regenerative medicine using stem cell therapy is accompanied by increased regulatory and clinical risk. The company’s lead program (AST-OPC1) is a pluripotent stem cell platform, a cell line derived from embryonic stem cells. Pluripotent stem cells are “master cells” and have the potential to differentiate into any cell type, as well as reproduce indefinitely. AST’s pluripotent stem cells, AST-OPC1, are differentiated into oligodendrocyte progenitor cells, which are glial cells in the central nervous system. AST-OPC1 is being developed for spinal cord injuries (SCIs) and is in a Phase I/IIa trial testing higher doses for safety and efficacy. There is no cure or effective therapy approved for SCI that can rehabilitate patients." (3/7/2017)

Are investors shorting Asterias Biotherapeutics?

Asterias Biotherapeutics saw a decrease in short interest in October. As of October 31st, there was short interest totalling 2,461,720 shares, a decrease of 12.1% from the October 13th total of 2,800,014 shares. Based on an average daily volume of 294,067 shares, the short-interest ratio is presently 8.4 days. Currently, 7.8% of the company's shares are sold short.

Who are some of Asterias Biotherapeutics' key competitors?

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:

  • Don M. Bailey, Chairman of the Board (Age 70)
  • Michael H. Mulroy, President, Chief Executive Officer, Director (Age 51)
  • Ryan Daniel Chavez, Chief Financial Officer, General Counsel (Age 40)
  • Katharine E. Spink Ph.D., Chief Operating Officer, Executive Vice President (Age 40)
  • Casey C. Case Ph.D., Senior Vice President - Research and Nonclinical Development (Age 59)
  • Jane S. Lebkowski Ph.D., Chief Scientific Officer (Age 58)
  • Edward D. Wirth III, Chief Medical Officer (Age 50)
  • Stephen L. Cartt, Director (Age 53)
  • Alfred D. Kingsley, Director (Age 74)
  • Aditya P. Mohanty, Director (Age 50)

Who owns Asterias Biotherapeutics stock?

Asterias Biotherapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Broadwood Capital Inc. (6.85%). Company insiders that own Asterias Biotherapeutics stock include Alfred D Kingsley, Edward Wirth, Katharine E Spink, Michael H Mulroy, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt. View Institutional Ownership Trends for Asterias Biotherapeutics.

Who sold Asterias Biotherapeutics stock? Who is selling Asterias Biotherapeutics stock?

Asterias Biotherapeutics' stock was sold by a variety of institutional investors in the last quarter, including Broadwood Capital Inc.. Company insiders that have sold Asterias Biotherapeutics company stock in the last year include Edward Wirth and Katharine E Spink. View Insider Buying and Selling for Asterias Biotherapeutics.

How do I buy Asterias Biotherapeutics stock?

Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of Asterias Biotherapeutics stock can currently be purchased for approximately $2.45.

How big of a company is Asterias Biotherapeutics?

Asterias Biotherapeutics has a market capitalization of $130.02 million.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.

MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  38
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Asterias Biotherapeutics (NYSEAMERICAN:AST)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.33

Consensus Price Target History for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Price Target History for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Analysts' Ratings History for Asterias Biotherapeutics (NYSEAMERICAN:AST)

DateFirmActionRatingPrice TargetDetails
10/2/2017HC WainwrightReiterated RatingBuy$12.00View Rating Details
4/4/2017LaidlawInitiated CoverageBuy -> Buy$12.00View Rating Details
3/7/2017FBR & CoBoost Price TargetOutperform$6.00 -> $10.00View Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
(Data available from 11/18/2015 forward)


Earnings History and Estimates Chart for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Earnings by Quarter for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Earnings History by Quarter for Asterias Biotherapeutics (NYSEAMERICAN AST)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.18)($0.18)$1.25 million$0.32 millionViewN/AView Earnings Details
3/28/2017Q4($0.17)($0.18)$2.81 million$1.75 millionViewN/AView Earnings Details
11/14/2016Q316($0.17)($0.24)$1.50 million$2.10 millionViewN/AView Earnings Details
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Asterias Biotherapeutics (NYSEAMERICAN:AST)

No earnings estimates for this company have been tracked by


Dividend History for Asterias Biotherapeutics (NYSEAMERICAN:AST)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Asterias Biotherapeutics (NYSEAMERICAN AST)

Insider Trades by Quarter for Asterias Biotherapeutics (NYSEAMERICAN:AST)
Institutional Ownership by Quarter for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Insider Trades by Quarter for Asterias Biotherapeutics (NYSEAMERICAN AST)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/25/2017Michael H MulroyInsiderBuy1,939$2.55$4,944.45View SEC Filing  
9/25/2017Michael H. MulroyInsiderBuy1,537$3.25$4,995.25View SEC Filing  
1/9/2017Edward WirthInsiderSell3,415$4.60$15,709.00View SEC Filing  
1/9/2017Katharine E SpinkCOOSell4,781$4.60$21,992.60View SEC Filing  
10/6/2016Edward WirthInsiderSell3,415$4.12$14,069.80View SEC Filing  
10/6/2016Katharine E. SpinkCOOSell4,781$4.11$19,649.91View SEC Filing  
9/9/2016Edward WirthInsiderSell14,760$3.52$51,955.20View SEC Filing  
9/9/2016Katharine E. SpinkCOOSell19,336$3.52$68,062.72View SEC Filing  
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.00View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  
9/16/2015Cary PinkowskiDirectorSell409,000$0.02$6,135.00
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
9/14/2015Cary PinkowskiDirectorSell394,000$0.02$5,910.00
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Latest Headlines for Asterias Biotherapeutics (NYSEAMERICAN AST)


Social Media

Social activity is not available for this stock.



Asterias Biotherapeutics (NYSEAMERICAN AST) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.